Compare Torrent Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs GSK PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA GSK PHARMA TORRENT PHARMA/
GSK PHARMA
 
P/E (TTM) x 63.0 214.9 29.3% View Chart
P/BV x 7.5 9.6 78.1% View Chart
Dividend Yield % 0.8 1.7 49.3%  

Financials

 TORRENT PHARMA   GSK PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
GSK PHARMA
Mar-19
TORRENT PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,9643,595 54.6%   
Low Rs1,2451,253 99.4%   
Sales per share (Unadj.) Rs453.4184.7 245.5%  
Earnings per share (Unadj.) Rs25.826.3 98.1%  
Cash flow per share (Unadj.) Rs62.329.2 213.6%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.10.8 128.4%  
Book value per share (Unadj.) Rs279.2126.3 221.0%  
Shares outstanding (eoy) m169.22169.40 99.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.513.1 27.0%   
Avg P/E ratio x62.292.2 67.5%  
P/CF ratio (eoy) x25.883.1 31.0%  
Price / Book Value ratio x5.719.2 29.9%  
Dividend payout %65.976.1 86.7%   
Avg Mkt Cap Rs m271,513410,626 66.1%   
No. of employees `00013.65.0 274.2%   
Total wages/salary Rs m14,0385,372 261.3%   
Avg. sales/employee Rs Th5,642.66,306.7 89.5%   
Avg. wages/employee Rs Th1,032.41,083.1 95.3%   
Avg. net profit/employee Rs Th320.9898.0 35.7%   
INCOME DATA
Net Sales Rs m76,72831,281 245.3%  
Other income Rs m5711,023 55.8%   
Total revenues Rs m77,29932,304 239.3%   
Gross profit Rs m19,8316,009 330.0%  
Depreciation Rs m6,177486 1,271.0%   
Interest Rs m5,0386 83,958.3%   
Profit before tax Rs m9,1876,540 140.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,570287 -1,243.9%   
Tax Rs m1,2542,373 52.8%   
Profit after tax Rs m4,3634,454 98.0%  
Gross profit margin %25.819.2 134.5%  
Effective tax rate %13.636.3 37.6%   
Net profit margin %5.714.2 39.9%  
BALANCE SHEET DATA
Current assets Rs m50,37520,061 251.1%   
Current liabilities Rs m51,65314,543 355.2%   
Net working cap to sales %-1.717.6 -9.4%  
Current ratio x1.01.4 70.7%  
Inventory Days Days9257 162.2%  
Debtors Days Days6814 485.7%  
Net fixed assets Rs m83,64814,343 583.2%   
Share capital Rs m8461,694 50.0%   
"Free" reserves Rs m46,39719,704 235.5%   
Net worth Rs m47,24421,398 220.8%   
Long term debt Rs m39,1292 1,956,460.0%   
Total assets Rs m141,20939,113 361.0%  
Interest coverage x2.81,091.0 0.3%   
Debt to equity ratio x0.80 886,151.5%  
Sales to assets ratio x0.50.8 67.9%   
Return on assets %6.711.4 58.4%  
Return on equity %9.220.8 44.4%  
Return on capital %12.331.9 38.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,103534 4,139.1%   
Fx outflow Rs m5,5227,091 77.9%   
Net fx Rs m16,581-6,557 -252.9%   
CASH FLOW
From Operations Rs m17,9813,994 450.2%  
From Investments Rs m-2,413-1,433 168.3%  
From Financial Activity Rs m-13,145-3,584 366.8%  
Net Cashflow Rs m2,380-1,023 -232.6%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 7.0 10.2 68.8%  
FIIs % 12.6 23.8 52.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 102,036 26.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

TORRENT PHARMA Surges by 7%; BSE HEALTHCARE Index Up 3.3% (Market Updates)

Apr 3, 2020 | Updated on Apr 3, 2020

TORRENT PHARMA share price has surged by 7% and its current market price is Rs 2,106. The BSE HEALTHCARE is up by 3.3%. The top gainers in the BSE HEALTHCARE Index are TORRENT PHARMA (up 6.9%) and APOLLO HOSPITALS (up 7.3%). The top losers are BLISS GVS PHARMA (down 0.1%) and GSK PHARMA (down 0.5%).

WOCKHARDT Surges by 6%; BSE HEALTHCARE Index Up 3.2% (Market Updates)

Apr 3, 2020 | Updated on Apr 3, 2020

WOCKHARDT share price has surged by 6% and its current market price is Rs 192. The BSE HEALTHCARE is up by 3.2%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.8%) and TORRENT PHARMA (up 7.2%). The top losers are BLISS GVS PHARMA (down 0.1%) and ABBOTT INDIA (down 0.4%).

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 3, 2020 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS